Discussions were lively at the “Digitization of Clinical Development & Clinical Trials” symposium at last week’s Bio-IT World conference. Addressing an audience of biotech and pharma IT and data leaders, QuartzBio’s Tobi Guennel gave a provocative presentation on how deploying generative AI can amplify the ability of precision medicine approaches to accelerate drug development.
Last week, biomarker intelligence leaders from Boston-area R&D organizations got a firsthand look at the powerful predictive and prescriptive intelligence that will soon infuse QuartzBio’s AI Biomarker Intelligence Platform, after sharing common challenges facing data-rich precision medicine clinical programs.
Tobi Guennel, PhD, QuartzBio’s Senior Vice President of Product & Chief Architect, energized the Biomarkers & Precision Medicine track at SCOPE 2024 by showing how generative AI can address challenges faced biospecimen and biomarker operations teams, as well as clinical and translational teams, when gathering insights on samples across all parts of a complex biomarker data ecosystem.
Learn how conversational AI enables you to talk to your biospecimen data. Join Bill Hall for a demo of our virtual Sample Inventory Management solution, powered by an AI-enabled Biomarker Intelligence Platform and intuitive Virtual Assistant.
QuartzBio’s team has deep experience in technology-enabled solutions for the life science industry. In this blog series, we invited you to get to know a member of the QuartzBio team. This month, we are delighted to talk with Katie Berola, Director of virtual Sample Inventory Management.
In a recent article titled, “The Criticality of Specimen Management to Precision Medicine,” Brenda Yanak warned drug developers against minimizing the importance of biospecimens, so often overlooked during biomarker development.
Join Bill Hall for a webinar demo of the QuartzBio® enterprise Biomarker Data Management solution. We’ll show you how to generate patient profiles to view tumor burden over course of treatment, explore multi-marker views of patient profiles, and cross-reference biomarker measures across file types.
Join our webinar to learn how our clients, representing major biopharmas and biotechnology companies, have eliminated tedious data management processes and costly delays with the QuartzBio® virtual Sample Inventory Management SaaS solution.
Precision for Medicine, the first global, precision medicine, clinical research services organization today announced the strategic acquisition of SolveBio, which will now fall under the QuartzBio, part of Precision for Medicine brand and product portfolio.
Translational and clinical teams spend more than 70% of their time managing, cleaning, and harmonizing data generated in biomarker-rich clinical programs. In a recent webinar, Adam Brown demonstrated how the QuartzBio® enterprise Biomarker Data Management (eBDM) solution addresses one set of frequently intractable challenges: connecting raw, processed, and ancillary data across multiple clinical studies.
Precision for Medicine is the first biomarker-driven clinical development organization supporting life sciences companies in the use of biomarkers essential to targeting patient treatments. Precision for Medicine is part of Precision Medicine Group, with 3,000 employees in 40 locations.
QUARTZBIO® and the PRECISION QUARTZBIO® logo are registered trademarks of Precision Medicine Group, LLC in the United States and/or other jurisdictions. All rights reserved.
© 2024. All rights reserved.
Precision Medicine Group, LLC.
Privacy Policy | GDPR
Web Design and Development by RainCastle Communications.